Serum detection of blood brain barrier injury in subjects with a history of stroke and transient ischemic attack.

Blood-based biomarkers Blood-brain barrier Endothelial inflammation Ischemic attack Stroke Transient

Journal

JVS-vascular science
ISSN: 2666-3503
Titre abrégé: JVS Vasc Sci
Pays: United States
ID NLM: 101767073

Informations de publication

Date de publication:
2024
Historique:
received: 18 02 2024
accepted: 13 04 2024
medline: 14 6 2024
pubmed: 14 6 2024
entrez: 14 6 2024
Statut: epublish

Résumé

Stroke and transient ischemic attack may have long-term negative effects on the blood-brain barrier (BBB) and promote endothelial inflammation, both of which could increase neurodegeneration and dementia risk beyond the cell death associated with the index event. Serum from 88 postmortem subjects in the Arizona Study of Aging and Neurodegenerative Disorders were analyzed by sandwich ELISA for specific biomarkers to investigate the effects of cerebrovascular accidents (CVAs) on BBB integrity and endothelial activation. Statistical analyses were performed using the Mann-Whitney Serum PDGFRẞ, a putative biomarker of BBB injury, was significantly increased in subjects with vs without a history of CVA who had similar cardiovascular risk factors ( Our data suggest that patients with stroke or transient ischemic attack have lasting changes in the BBB. Still more, this demonstrates the utility of PDGFRẞ as a serum-based biomarker of BBB physiology, a potentially powerful tool in studying the role of the BBB in various neurodegenerative diseases and COVID infection sequelae. Our data demonstrate the utility of serum PDGFRẞ, a putative biomarker of BBB integrity in the setting of stroke and TIA (CVA). A serum biomarker of BBB integrity could be a useful tool to detect early BBB damage and allow prospective work to study how such damage affects long-term neurodegenerative risk. Since BBB disruption occurs early in ADRD development, it could be monitored to help better understand disease progression and involvement of vascular pathways in ADRD.

Identifiants

pubmed: 38873494
doi: 10.1016/j.jvssci.2024.100206
pii: S2666-3503(24)00017-8
pmc: PMC11170223
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100206

Informations de copyright

© 2024 by the Society for Vascular Surgery. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

None.

Auteurs

Scott French (S)

The Division of Vascular Surgery, University of Arizona, and Sarver Heart Center, Tucson, AZ.

Juan Arias (J)

The Division of Vascular Surgery, University of Arizona, and Sarver Heart Center, Tucson, AZ.

Ikeoluwapo Bolakale-Rufai (I)

The Division of Vascular Surgery, University of Arizona, and Sarver Heart Center, Tucson, AZ.

Summan Zahra (S)

The Division of Vascular Surgery, University of Arizona, and Sarver Heart Center, Tucson, AZ.

Kaneez Zahra Rubab Khakwani (KZ)

The Division of Vascular Surgery, University of Arizona, and Sarver Heart Center, Tucson, AZ.

Edward J Bedrick (EJ)

Department of Epidemiology and Biostatistics, University of Arizona College of Public Health, Tucson, AZ.

Geidy E Serrano (GE)

Banner Sun Health Research Institute, Sun City, AZ.

Thomas G Beach (TG)

Banner Sun Health Research Institute, Sun City, AZ.

Eric Reiman (E)

Banner Alzheimer's Institute, University of Arizona, Arizona State University, Translational Genomics Research Institute, and Arizona Alzheimer's Consortium, Phoenix, AZ.

Craig Weinkauf (C)

The Division of Vascular Surgery, University of Arizona, and Sarver Heart Center, Tucson, AZ.

Classifications MeSH